We are live on
!
Find out more
VCM
Versant Capital Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
34.21%
This Fund
S&P 500
This Quarter
Est. Return
+13.52%
1 Year Est. Return
+34.21%
3 Year Est. Return
+82.39%
5 Year Est. Return
+89.4%
10 Year Est. Return
+245.39%
AUM
$1.12B
AUM Growth
+$101M
(+10%)
Cap. Flow
+$19.1M
Cap. Flow
% of AUM
1.71%
Top 10 Holdings %
Top 10 Hldgs %
31.56%
Holding
2,873
New
96
Increased
1,181
Reduced
859
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DXUV
Dimensional US Vector Equity ETF
DXUV
|
+$8.37M |
| 2 |
Dimensional Emerging Markets Core Equity 2 ETF
DFEM
|
+$7.66M |
| 3 |
iShares Core S&P Mid-Cap ETF
IJH
|
+$6.75M |
| 4 |
DXIV
Dimensional International Vector Equity ETF
DXIV
|
+$4.35M |
| 5 |
Dimensional Emerging Markets Value ETF
DFEV
|
+$2.47M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 3-7 Year Treasury Bond ETF
IEI
|
+$2.11M |
| 2 |
iShares 5-10 Year Investment Grade Corporate Bond ETF
IGIB
|
+$2.02M |
| 3 |
Vanguard Total Stock Market ETF
VTI
|
+$1.88M |
| 4 |
CoreCivic
CXW
|
+$1.84M |
| 5 |
Apple
AAPL
|
+$1.34M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.06% |
| 2 | Financials | 7.05% |
| 3 | Industrials | 6.04% |
| 4 | Consumer Discretionary | 4.74% |
| 5 | Healthcare | 4.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2501
Xperi
XPER
$358M
| $3.49K | ﹤0.01% |
424
-1,103
| -72% | -$7.98K |
|
2502
Universal Logistics Holdings
ULH
$435M
| $3.46K | ﹤0.01% |
234
-834
| -78% | -$14.9K |
|
2503
Inspired Entertainment
INSE
$175M
| $3.43K | ﹤0.01% |
416
| – | – |
|
2504
Protagonist Therapeutics
PTGX
$8.71B
| $3.31K | ﹤0.01% |
27
| – | – |
|
2505
Medifast
MED
$105M
| $3.29K | ﹤0.01% |
310
+51
| +20% | +$588 |
|
2506
PRA Group
PRAA
$616M
| $3.17K | ﹤0.01% |
167
-301
| -64% | -$5.35K |
|
2507
American Public Education
APEI
$884M
| $3.17K | ﹤0.01% |
59
| – | – |
|
2508
Option Care Health
OPCH
$3.31B
| $3.17K | ﹤0.01% |
151
+4
| +3% | +$93 |
|
2509
Lakeland Financial Corp
LKFN
$1.52B
| $3.15K | ﹤0.01% |
51
| – | – |
|
2510
Forward Air
FWRD
$490M
| $3.13K | ﹤0.01% |
232
-566
| -71% | -$8.43K |
|
2511
Credicorp
BAP
$30.8B
| $3.12K | ﹤0.01% |
8
+1
| +14% | +$342 |
|
2512
Castle Biosciences
CSTL
$773M
| $3K | ﹤0.01% |
126
-120
| -49% | -$2.67K |
|
|
AIV
2513
Aimco
AIV
$380M
| $2.99K | ﹤0.01% |
1,006
-614
| -38% | -$2.35K |
|
2514
Doximity
DOCS
$3.68B
| $2.97K | ﹤0.01% |
143
-1,465
| -91% | -$32.4K |
|
2515
Sensient Technologies
SXT
$4.98B
| $2.96K | ﹤0.01% |
24
-118
| -83% | -$13.1K |
|
2516
Cimpress
CMPR
$2.36B
| $2.95K | ﹤0.01% |
29
+12
| +71% | +$1.07K |
|
2517
FuboTV Inc
FUBO
$254M
| $2.94K | ﹤0.01% |
+320
| New | +$3.41K |
|
2518
Invesco S&P 500 Quality ETF
SPHQ
$19.4B
| $2.88K | ﹤0.01% |
32
| – | – |
|
2519
Acadia Healthcare
ACHC
$3.13B
| $2.81K | ﹤0.01% |
95
+12
| +14% | +$308 |
|
2520
Dolby
DLB
$4.65B
| $2.79K | ﹤0.01% |
53
-7
| -12% | -$401 |
|
2521
CG Oncology
CGON
$6.27B
| $2.77K | ﹤0.01% |
39
| – | – |
|
2522
Bioventus
BVS
$778M
| $2.77K | ﹤0.01% |
293
| – | – |
|
|
NTST
2523
NETSTREIT Corp
NTST
$2.12B
| $2.75K | ﹤0.01% |
130
| – | – |
|
2524
Vanguard Global ex-US Real Estate ETF
VNQI
$3.44B
| $2.74K | ﹤0.01% |
61
-64
| -51% | -$2.95K |
|
|
ELVR
2525
Elevra Lithium Ltd
ELVR
$958M
| $2.73K | ﹤0.01% |
40
| – | – |
|
Similar funds
FLAM
AIM
MTCM
CNC
NOSC
RIM
ACG
C
Versant Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Versant Capital Management held 2,873 positions worth $1.12B, up 10% from $1.01B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Versant Capital Management's Q2 2026 filing shows 96 new, 1,181 increased, 859 reduced and 128 closed positions. Its largest new stake was AstraZeneca: 7,263 shares worth $1.36M. The largest sale was iShares 3-7 Year Treasury Bond ETF, an estimated $2.11M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Financials and Industrials.
- Versant Capital Management's largest Q2 2026 buy was AstraZeneca: 7,263 shares worth $1.36M.
- Versant Capital Management added most to Dimensional US Vector Equity ETF in Q2 2026, an estimated $8.37M increase.
- Versant Capital Management's biggest Q2 2026 reduction was iShares 3-7 Year Treasury Bond ETF, cutting an estimated $2.11M.
- Versant Capital Management fully exited iShares 5-10 Year Investment Grade Corporate Bond ETF in Q2 2026, selling an estimated $2.02M.
- Versant Capital Management's ten largest holdings make up 32% of its $1.12B portfolio in Q2 2026.
- Versant Capital Management opened 96 new positions and closed 128 in Q2 2026.
- Versant Capital Management's portfolio value rose 10% quarter-over-quarter to $1.12B.
Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.